-
1.发明申请公开(公告)号：US20190216946A1
公开(公告)日：2019-07-18
申请号：US16362562
申请日：2019-03-22
IPC分类号： A61K47/69 , A61K31/706 , A61K9/50 , A61K31/65
CPC分类号： A61K47/6901 , A61K9/5068 , A61K31/65 , A61K31/706
摘要： Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages.
-
2.发明授权公开(公告)号：US10426736B2
公开(公告)日：2019-10-01
申请号：US15675548
申请日：2017-08-11
IPC分类号： A61K48/00 , C07H21/02 , C07H21/04 , C12N15/113 , A61K9/50 , C07K16/12 , C07K16/28 , C12N15/11 , A61K31/713 , A61K47/46 , A61K39/40 , C07K16/40 , A61K31/4745 , A61K39/395 , A61K47/69
摘要： Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
-
3.发明申请公开(公告)号：US20170258734A1
公开(公告)日：2017-09-14
申请号：US15604555
申请日：2017-05-24
IPC分类号： A61K9/50 , C07K16/28 , C12N15/11 , C12N15/113 , A61K31/713 , A61K48/00 , A61K31/4745 , A61K39/395 , C07K16/40 , A61K39/40 , C07K16/12 , A61K47/46
CPC分类号： A61K9/5068 , A61K31/4745 , A61K31/713 , A61K39/39558 , A61K39/40 , A61K47/46 , A61K47/6901 , A61K47/6923 , A61K48/0008 , C07K16/1235 , C07K16/2863 , C07K16/40 , C07K2317/31 , C12N15/111 , C12N15/113 , C12N15/1135 , C12N15/1137 , C12N15/1138 , C12N2310/11 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/531 , C12N2320/32 , Y02A50/473
摘要： Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
-
公开(公告)号：US11504402B2
公开(公告)日：2022-11-22
申请号：US16518833
申请日：2019-07-22
摘要： Compositions and methods for treating cancer are provided. In particular, the compositions comprise an anti-neoplastic agent and either an interferon type I agonist or an interferon type II agonist, or a combination of an interferon type I agonist and an interferon type II agonist.
-
5.发明授权公开(公告)号：US10583200B2
公开(公告)日：2020-03-10
申请号：US15997238
申请日：2018-06-04
IPC分类号： A61K48/00 , C12N15/88 , A61K47/69 , A61K39/395 , A61K39/00
摘要： A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
-
6.发明申请公开(公告)号：US20180369416A1
公开(公告)日：2018-12-27
申请号：US15997238
申请日：2018-06-04
摘要： A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
-
公开(公告)号：US10799461B2
公开(公告)日：2020-10-13
申请号：US15870000
申请日：2018-01-12
IPC分类号： A61K9/50 , A61K31/704 , A61K47/68 , A61K47/69
摘要： A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
